Observational pilot single-center study aiming to determine the microbiota of critically ill patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical critically ill controls with no SARS-CoV-2 infection.
Observational pilot single-center study aiming to determine the microbiota of critically ill
patients infected with SARS-CoV-2. COVID-19 patients will be compared to historical
critically ill controls with no SARS-CoV-2 infection.
Respiratory and fecal microbiota (microbial and fungal) will be determined in COVID-19
patients on bronchoalveolar lavage and rectal swab.
Inflammatory biomarkers will also be measured in COVID-19 patients.
Characteristics of study patients will be collected at ICU admission and during ICU stay.
Inclusion Criteria:
For the Covid-19 Group: with a confirmed severe lung infection with CoV2-SARS-Cov2 admitted
to the ICU.
For the Control Group:
- Historic cohort of non SARS -CoV2-infected adults admitted to the ICU (between March
and October 2019),
- that was investigated for fecal microbiota in a previous study (control patients in a
fecal microbiota study in patients included in the SEAT study).
Exclusion Criteria:
- For the Covid-19 group:
- Lack of coverage Patients who received antibiotic therapy within 6 weeks prior to
Covid-19 symptomatology,
- Pregnant women,
- Severe immunosuppression: Neutropenia < 0.5 G/L, Chemotherapy < 6 months, Bone marrow
transplant recipients, HIV with CD4+ lymphocytes < 0.4 G/L
- Impossible to perform bronchoalveolar lavage,
- Non-socially insured,
- Refusal to participate in the social study
Hôpital Roger Salengro, CHU Lille
Lille, France
Saad Nseir, MD,PhD, Principal Investigator
University Hospital, Lille